Clinical application of Huanyang Tongluo moxibustion in interventional therapy of primary hepatic carcinoma

doi:10.3877/cma.j.issn.2095-2015.2024.03.002

Abstract

Abstract:

Objective

To analyze the clinical application effect and safety of Huanyang Tongluo moxibustion in interventional therapy of liver cancer.

Methods

Eighty patients with liver cancer admitted to Xuzhou Cancer Hospital from June 2021 to June 2023 were randomly divided into the observation group (n=40) and the control group (n=40). Both groups were treated by transcatheter hepatic arterial chemoembolization (TACE), and the observation group was treated with Huanyang Tongluo moxibustion. The changes of pain visual analogue scale (VAS), serum β-endorphin (β-EP), 5-hydroxytryptamine (5-HT), Karnofsky performance status (KPS) score and core quality of life scale for cancer patients (EORTC QLQ-C30) were compared between the two groups before and after treatment, and the clinical efficacy and nausea and vomiting occurrence of the two groups were compared.

Results

After one month and three months of treatment, the VAS score and β-EP of the two groups decreased (P<0.05), while the 5-HT score, KPS score and EORTC QLQ-C30 score increased (P<0.05). The VAS score and β-EP in the observation group after treatment were lower than those in the control group (P<0.05), while the 5-HT score, KPS score and EORTC QLQ-C30 score were higher than those in the control group (P<0.05). After 3 months of treatment, the total effective rate of the observation group was higher than that of the control group (82.50% vs. 60.00%, P<0.05). During the treatment period, the incidence and severity of nausea and vomiting in the observation group were lower than those in the control group (P<0.05).

Conclusion

Huanyang Tongluo moxibustion can effectively relieve patients' physical pain, improve stress and emotional function, improve activity ability and quality of life, and may be beneficial to enhance the therapeutic effect of TACE and reduce nausea and vomiting of TACE.

Key words: Primary hepatic carcinoma, Transcatheter arterial chemoembolization, Huanyang Tongluo moxibustion, Security

Le Bao, Ying Liu, Youbin Wang, Long Chen, Yuzhi Zhu, Shuang Liang, Hetai Quan, Pengfei Li. Clinical application of Huanyang Tongluo moxibustion in interventional therapy of primary hepatic carcinoma[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(03): 197-202.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2024.03.002

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2024/V14/I03/197

Figures/Tables 7

References 19

[1]	刘公攀, 陈涛, 丁志刚, 等. CalliSpheres可载药微球经导管肝动脉化疗栓塞序贯射频消融治疗原发性肝癌患者疗效研究[J]. 实用肝脏病杂志, 2023, 26(6): 879-882.
[2]	Zhang XW, Gu YJ, Wu HG, et al. Systematic review and meta-analysis of acupuncture for pain caused by liver cancer[J]. World J Trad Chin Med, 2022, 8(3): 402-412.
[3]	张利捷, 梁斌. 免疫检查点阻断与肝癌化疗栓塞[J]. 介入放射学杂志, 2020, 29(4): 419-422.
[4]	Sun Y, Ji S, Ji H, et al. Clinical efficacy analysis of transcatheter arterial chemoembolization(TACE) combined with radiofrequency ablation(RFA) in primary liver cancer and recurrent liver cancer[J]. J buon, 2019, 24(4): 1402-1407.
[5]	王文刚, 宋震, 柳昂, 等. 卡瑞利珠单抗加酪氨酸激酶抑制剂联合肝动脉化疗栓塞在中晚期肝癌中的疗效及安全性[J]. 徐州医科大学学报, 2023, 43(7): 529-535.
[6]	Ren Y, Cao Y, Ma H, et al. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study[J]. BMC Cancer, 2019, 19(1): 1-10.
[7]	余张章, 赵恒昌. 奥沙利铂,顺铂化疗栓塞术治疗晚期肝癌的效果[J]. 临床医学研究与实践, 2019, 4(5): 20-22.
[8]	何敏柯, 赖志城, 石明. FOLFOX-肝动脉灌注化疗与经动脉化疗栓塞治疗肝癌的比较及临床选择[J/OL]. 肿瘤综合治疗电子杂志, 2023, 9(4): 22-26.
[9]	Li X, Chen B, An C, et al. Transarterial chemoembolization combined with microwave ablation versus microwave ablation only for Barcelona clinic liver cancer Stage B hepatocellular carcinoma: A propensity score matching study[J]. J Cancer Res Ther, 2020, 16(5): 1027-1037.
[10]	胡晓蕾, 尧银光, 刘素霞. 肝癌患者化疗栓塞术后早期外周血免疫细胞的变化[J]. 浙江临床医学, 2022, 24(1): 63-65.
[11]	Liao X, Bu Y, Jia Q. Traditional Chinese medicine as supportive care for the management of liver cancer: past, present, and future[J]. Genes Dis, 2020, 7(3): 370-379.
[12]	吴新民,罗爱伦,田玉科,等.术后恶心呕吐防治专家意见(2012)[J].临床麻醉学杂志, 2012, 28(4):413-416.
[13]	汪婷婷. 动脉灌注化疗栓塞术介入治疗肝癌的疗效分析[J]. 中国继续医学教育, 2021, 13(24): 155-157.
[14]	王昊, 单良, 吴孝雄, 等. 清肝祛癌方联合肝动脉化疗栓塞术治疗晚期热瘀型肝癌临床疗效[J]. 临床军医杂志, 2021, 49(3): 306-308.
[15]	梁国栋, 彭勇, 丛鹏. 载药微球经肝动脉化疗栓塞术联合系统性抗肿瘤方案治疗不可切除原发性肝癌的临床疗效及安全性研究[J]. 中国临床新医学, 2023, 16(11): 1153-1158.
[16]	Lyu N, Kong Y, Li X, et al. Effect and safety of prophylactic parecoxib for pain control of transarterial chemoembolization in liver cancer: a single-center, parallel-group, randomized trial[J]. J Am Coll Radiol, 2022, 19(1): 61-70.
[17]	刘保旺, 窦剑, 王洋, 等. 肝癌肝移植术前降期中载药微球经动脉化疗栓塞应用效果观察[J]. 河北医学, 2023, 29(7): 1183-1187.
[18]	王龙, 严清青, 陈国东. 肝癌导管肝动脉栓塞及与化疗栓塞的效果比较[J]. 深圳中西医结合杂志, 2021, 31(10): 128-130.
[19]	Liu K, Li H, Duan J, et al. Progress in clinical research on the integration of Chinese and Western medicines for treating primary liver cancer[J]. J Trad Chin Med Sci, 2021, 8(3): 173-185.

组别	例数	年龄(岁,±s)	体重指数(kg/m²,±s)	性别[例(%)]		TNM分期[例(%)]			Child-Pugh分级[例(%)]
组别	例数	年龄(岁,±s)	体重指数(kg/m²,±s)	男	女	Ⅱ期	Ⅲ期	Ⅳ期	A级	B级	C级
观察组	40	48.17±5.06	22.57±1.31	23(57.50)	17(42.50)	5(12.50)	17(42.50)	18(45.00)	29(72.50)	8(20.00)	3(7.50)
对照组	40	48.25±4.82	22.62±1.45	21(52.50)	19(47.50)	4(10.00)	20(50.00)	16(40.00)	32(80.00)	7(17.50)	1(2.50)
t/χ²值		0.072	0.162	0.202		0.205			0.621
P值		0.942	0.842	0.653		0.651			0.431

组别	例数	年龄(岁,±s)	体重指数(kg/m²,±s)	性别[例(%)]		TNM分期[例(%)]			Child-Pugh分级[例(%)]
组别	例数	年龄(岁,±s)	体重指数(kg/m²,±s)	男	女	Ⅱ期	Ⅲ期	Ⅳ期	A级	B级	C级
观察组	40	48.17±5.06	22.57±1.31	23(57.50)	17(42.50)	5(12.50)	17(42.50)	18(45.00)	29(72.50)	8(20.00)	3(7.50)
对照组	40	48.25±4.82	22.62±1.45	21(52.50)	19(47.50)	4(10.00)	20(50.00)	16(40.00)	32(80.00)	7(17.50)	1(2.50)
t/χ²值		0.072	0.162	0.202		0.205			0.621
P值		0.942	0.842	0.653		0.651			0.431

组别	例数	治疗前	治疗1个月后	治疗3个月后
观察组	40	2.81±0.35	2.24±0.17^*	1.69±0.08^*
对照组	40	2.76±0.29	2.35±0.16^*	1.85±0.11^*
t值		0.696	2.980	7.440
P值		0.489	0.004	<0.001

组别	例数	治疗前	治疗1个月后	治疗3个月后
观察组	40	2.81±0.35	2.24±0.17^*	1.69±0.08^*
对照组	40	2.76±0.29	2.35±0.16^*	1.85±0.11^*
t值		0.696	2.980	7.440
P值		0.489	0.004	<0.001

组别	例数	β-内啡肽			5-羟色胺
组别	例数	术前	术后1 d	术后15 d	术前	术后1 d	术后15 d
观察组	40	89.42±15.35	82.27±11.96^*	74.57±8.54^*	438.45±54.62	475.92±58.49^*	499.64±64.18^*
对照组	40	88.97±16.12	88.05±12.54^*	79.75±8.96^*	437.68±55.81	437.64±59.61^*	462.65±62.76^*
t值		0.128	2.110	2.647	0.062	2.899	2.606
P值		0.899	0.038	0.010	0.950	0.005	0.011

Please choose a citation manager

Content to export